The Behaviour of 5-Hydroxymethylcytosine in Bisulfite Sequencing

Background We recently showed that enzymes of the TET family convert 5-mC to 5-hydroxymethylcytosine (5-hmC) in DNA. 5-hmC is present at high levels in embryonic stem cells and Purkinje neurons. The methylation status of cytosines is typically assessed by reaction with sodium bisulfite followed by PCR amplification. Reaction with sodium bisulfite promotes cytosine deamination, whereas 5-methylcytosine (5-mC) reacts poorly with bisulfite and is resistant to deamination. Since 5-hmC reacts with bisulfite to yield cytosine 5-methylenesulfonate (CMS), we asked how DNA containing 5-hmC behaves in bisulfite sequencing. Methodology/Principal Findings We used synthetic oligonucleotides with different distributions of cytosine as templates for generation of DNAs containing C, 5-mC and 5-hmC. The resulting DNAs were subjected in parallel to bisulfite treatment, followed by exposure to conditions promoting cytosine deamination. The extent of conversion of 5-hmC to CMS was estimated to be 99.7%. Sequencing of PCR products showed that neither 5-mC nor 5-hmC undergo C-to-T transitions after bisulfite treatment, confirming that these two modified cytosine species are indistinguishable by the bisulfite technique. DNA in which CMS constituted a large fraction of all bases (28/201) was much less efficiently amplified than DNA in which those bases were 5-mC or uracil (the latter produced by cytosine deamination). Using a series of primer extension experiments, we traced the inefficient amplification of CMS-containing DNA to stalling of Taq polymerase at sites of CMS modification, especially when two CMS bases were either adjacent to one another or separated by 1–2 nucleotides. Conclusions We have confirmed that the widely used bisulfite sequencing technique does not distinguish between 5-mC and 5-hmC. Moreover, we show that CMS, the product of bisulfite conversion of 5-hmC, tends to stall DNA polymerases during PCR, suggesting that densely hydroxymethylated regions of DNA may be underrepresented in quantitative methylation analyses.

[1]  K. Patterson,et al.  DNA Methylation: Bisulphite Modification and Analysis , 2011, Journal of visualized experiments : JoVE.

[2]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[3]  M. Carroll,et al.  A common genetic mechanism in malignant bone marrow diseases. , 2009, The New England journal of medicine.

[4]  J. Soulier,et al.  Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.

[5]  Lee E. Edsall,et al.  Human DNA methylomes at base resolution show widespread epigenomic differences , 2009, Nature.

[6]  Anne H. O'Donnell,et al.  Mammalian cytosine methylation at a glance , 2009, Journal of Cell Science.

[7]  A. Hagemeijer,et al.  Acquired mutations in TET2 are common in myelodysplastic syndromes , 2009, Nature Genetics.

[8]  C. Mullighan TET2 mutations in myelodysplasia and myeloid malignancies , 2009, Nature Genetics.

[9]  Jungwon Huh,et al.  Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. , 2009, Blood.

[10]  Z. Liutkevičiūtė,et al.  Cytosine-5-methyltransferases add aldehydes to DNA. , 2009, Nature chemical biology.

[11]  R. Lister,et al.  Finding the fifth base: genome-wide sequencing of cytosine methylation. , 2009, Genome research.

[12]  David R. Liu,et al.  Conversion of 5-Methylcytosine to 5- Hydroxymethylcytosine in Mammalian DNA by the MLL Partner TET1 , 2009 .

[13]  N. Heintz,et al.  The Nuclear DNA Base 5-Hydroxymethylcytosine Is Present in Purkinje Neurons and the Brain , 2009, Science.

[14]  E. Thiel,et al.  The MLL recombinome of adult CD10-negative B-cell precursor acute lymphoblastic leukemia: results from the GMALL study group. , 2009, Blood.

[15]  D. Gilliland,et al.  Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML , 2009, Leukemia.

[16]  D. Gilliland,et al.  TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis , 2009, Leukemia.

[17]  A. Feinberg,et al.  Genome-wide methylation analysis of human colon cancer reveals similar hypo- and hypermethylation at conserved tissue-specific CpG island shores , 2008, Nature Genetics.

[18]  M. Krzywinski,et al.  New insights to the MLL recombinome of acute leukemias , 2009, Leukemia.

[19]  D. Gilliland,et al.  Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates , 2009, Leukemia.

[20]  T. Mikkelsen,et al.  Genome-scale DNA methylation maps of pluripotent and differentiated cells , 2008, Nature.

[21]  Stephan Beck,et al.  The methylome: approaches for global DNA methylation profiling. , 2008, Trends in genetics : TIG.

[22]  S. Nelson,et al.  Shotgun bisulphite sequencing of the Arabidopsis genome reveals DNA methylation patterning , 2008, Nature.

[23]  Peter A. Jones,et al.  Cancer epigenetics: modifications, screening, and therapy. , 2008, Annual review of medicine.

[24]  Steven Henikoff,et al.  Genome-wide analysis of DNA methylation patterns , 2007, Development.

[25]  Christoph Plass,et al.  Unraveling the epigenetic code of cancer for therapy. , 2007, Trends in genetics : TIG.

[26]  Michael Weber,et al.  Genomic patterns of DNA methylation: targets and function of an epigenetic mark. , 2007, Current Opinion in Cell Biology.

[27]  W. Reik Stability and flexibility of epigenetic gene regulation in mammalian development , 2007, Nature.

[28]  M. Esteller Cancer epigenomics: DNA methylomes and histone-modification maps , 2007, Nature Reviews Genetics.

[29]  L. Sowers,et al.  Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. , 2007, Cancer research.

[30]  S. Doublié,et al.  A structural rationale for stalling of a replicative DNA polymerase at the most common oxidative thymine lesion, thymine glycol , 2007, Proceedings of the National Academy of Sciences.

[31]  D. Dietrich,et al.  Control of carry-over contamination for PCR-based DNA methylation quantification using bisulfite treated DNA , 2006, Nucleic acids research.

[32]  Kenny Q. Ye,et al.  Comparative isoschizomer profiling of cytosine methylation: the HELP assay. , 2006, Genome research.

[33]  A. Bird,et al.  Genomic DNA methylation: the mark and its mediators. , 2006, Trends in biochemical sciences.

[34]  T. Bestor,et al.  Eukaryotic cytosine methyltransferases. , 2005, Annual review of biochemistry.

[35]  A. Bird,et al.  Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). , 2004, Nucleic acids research.

[36]  S. Mathew,et al.  TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23) , 2003, Leukemia.

[37]  Y. Hayashi,et al.  LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). , 2002, Cancer research.

[38]  W. Reik,et al.  Epigenetic Reprogramming in Mammalian Development , 2001, Science.

[39]  A. Bird,et al.  Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. DePamphilis,et al.  Identifying 5-methylcytosine and related modifications in DNA genomes. , 1998, Nucleic acids research.

[41]  J. Clark,et al.  Thymine glycol lesions terminate chain elongation by DNA polymerase I in vitro. , 1986, Nucleic acids research.

[42]  M. Ehrlich,et al.  5-Methylcytosine in eukaryotic DNA. , 1981, Science.

[43]  A. Razin,et al.  Methylation of CpG sequences in eukaryotic DNA , 1981, FEBS letters.

[44]  H. Hayatsu,et al.  Reaction of bisulfite with the 5-hydroxymethyl group in pyrimidines and in phage DNAs. , 1979, Biochemistry.

[45]  Y. Wataya,et al.  Reaction of sodium bisulfite with uracil, cytosine, and their derivatives. , 1970, Biochemistry.